Home › Lymphoma › Pennsylvania
Pag-aaral pangklinika para sa Lymphoma sa Pennsylvania
22 pag-aaral para sa Lymphoma ang naghahanap ng mga kalahok sa mga site sa Pennsylvania.
Mga Lungsod sa Pennsylvania
Opisyal na teksto ng pag-aaral (English)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- University of Pennsylvania, Philadelphia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07015242A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Allegheny Health Network, Pittsburgh
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07188558A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- UPMC Hillman Cancer Center, Pittsburgh
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07221500Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06131801Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- The Children's Hospital of Philadelphia (CHOP), Philadelphia
Nagre-recruitPhase 1
24 Months – 18 Years · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT06441331Collection of Tissue Samples for Cancer Research
- University of Pittsburgh Medical Center, Pittsburgh
Nagre-recruitObservasyonal na pag-aaral
2 Months · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT00900198AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Philadelphia
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT06137144CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- UPMC Hilman Cancer Center, Pittsburgh
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT03328078Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Pittsburgh
Nagre-recruitPhase 3
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT07509151Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT04234048A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07192471A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
Nagre-recruitPhase 1/2
Hanggang edad 25 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04094610CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Nagre-recruitPhase 1/2
12 Months – 21 Years · Lahat ng kasarian · Na-update Set 11, 2026 · NCT04870944TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- Hospital of the University of Pennsylvania, Philadelphia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07082803Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Lehigh Valley Topper Cancer Center Institute, Allentown
- Thomas Jefferson University, Philadelphia
- West Penn Hospital, Pittsburgh
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04104776DALY II USA/ MB-CART2019.1 for DLBCL
- Allegheny Health Network Cancer Institute, Pittsburgh
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site 2, Pittsburgh
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Saint Christopher's Hospital for Children, Philadelphia
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 18, 2026 · NCT01790152Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- Community Medical Center, Scranton
- at 1 pa
Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 13, 2026 · NCT05006482CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
- University of Pennsylvania - Abramson Caner Center, Philadelphia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2025 · NCT06420089Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.